In-Licensing Service Everest Medicines Eyes HK IPO after USD 300 Mn Series C
COVID-19 and China
Mount Everest. Image credit: Andreas Gabler/Unsplash

Everest Medicines, the Zhejiang-based biotech startup, applied for an IPO on the Hong Kong Stock Exchange, only one month after a Series C fundraising of USD 310 million.

As an in-licensing biopharmaceutical company, Everest Medicines focuses on developing and commercializing innovative medicines. The product portfolio covers oncology, immunotherapy, infectious diseases and heart /kidney diseases.

Years of clinical trials have brought considerable losses – the year of 2019 recorded a loss as much of as much as CNY 176 million. Furthermore, the company already suffered a CNY 150 million loss in the first quarter of 2020.

However, a bright future may be on its way. Many pilot products have already entered Phase III – the critical stage in the clinical trial process. With rich experience in licensing and commercialization, the company looks likely to realize profits very soon.

See Also

Communicate Directly with the Author!

Ask the author questions about the copied text

Research Reports
Editor's Picks